Public Health Trace

Get Alerts

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters

Drug Recall Ongoing Historical recordClass II

Diphenhydramine 50 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Diclazuril 10 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Dextrose 50% Solution, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Dexpanthenol 250 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Dexamethasone Sodium Phosphate 6 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Detomidine w/Xylazine 100 mg/mg Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Detomidine 10 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Deslorelin 15 mg vial, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Cre-O-Pan Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Clenbuterol 0.03mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Chlorpromazine HCL 100 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Cal-Phos 1000 Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Calcium Gluconate 23%, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Caco/Copper 6. 2 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

BNP/Dexamethasone Eye Ointment, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Bi mix, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Betamethasone Phosphate/Acetate 6 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Betamethasone Sodium Phosphate 12 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Beta Alanine 100 mg/ml / l-carnosine 100 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Atropine Sulfate 50 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Data last updated: October 3, 2026 ET

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.